

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 9/12, 9/107</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/37051</b> <b>(43) International Publication Date:</b> 29 June 2000 (29.06.00)
<b>(21) International Application Number:</b> PCT/CA99/01231 <b>(22) International Filing Date:</b> 16 December 1999 (16.12.99)  <b>(30) Priority Data:</b> 60/113,239 21 December 1998 (21.12.98) US 09/251,464 17 February 1999 (17.02.99) US 09/386,284 31 August 1999 (31.08.99) US  <b>(71) Applicant (for all designated States except US):</b> GENEREX PHARMACEUTICALS INC. [CA/CA]; 202, 33 Harbour Square, Toronto, Ontario M5J 2G2 (CA).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> MODI, Pankaj [CA/CA]; 519 Golf Links Road, Ancaster, Ontario L9G 4X6 (CA).  <b>(74) Agents:</b> KAO, Dolly et al.; Barrigar & Moss, Suite 901, 2 Robert Speck Parkway, Mississauga, Ontario L4Z 1H8 (CA).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> AEROSOL FORMULATIONS FOR BUCCAL AND PULMONARY APPLICATION  <b>(57) Abstract</b>  A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxocholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate and deoxycholate. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt.% of the formulation. The propellant, e.g., a fluorocarbon propellant, provides enhanced absorption of the pharmaceutical agent, particularly in the buccal cavity.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AEROSOL FORMULATIONS FOR BUCCAL AND  
PULMONARY APPLICATION

This application is a continuation-in-part of  
5 application No. 09/251464 filed February 17, 1999, which  
is a continuation of provisional application  
No. 60/113239 filed December 21, 1998.

Field of the Invention

The present invention relates to an improved  
10 delivery system for the administration of large-molecule  
pharmaceuticals, e.g. peptidic drugs, vaccines and  
hormones. In particular it relates to pharmaceuticals  
which may be administered by means of an aerosol into  
the mouth, for buccal or pulmonary application.

15 Background to the Invention

In spite of significant efforts in academic and  
commercial laboratories, major breakthroughs in oral  
peptide and protein formulation have not been achieved.  
Relatively little progress has been made in reaching the  
20 target of safe and effective oral formulations for  
peptides and proteins. The major barriers to developing  
oral formulations for proteins and peptides include poor  
intrinsic permeability, lumenal and cellular enzymatic  
degradation, rapid clearance, and chemical stability in  
25 the gastrointestinal (GI) tract. Pharmaceutical  
approaches to address these barriers, which have been  
successful with traditional small, organic drug  
molecules, have not readily translated into effective  
peptide and protein formulations. Although the  
30 challenges are significant, the potential therapeutic  
benefits remain high especially in the field of diabetes  
treatment using insulin.

Scientists have explored various administration  
routes other than the injection for proteins and  
35 peptides. Oral and nasal cavities have been of greatest  
interest to scientists. Both the oral and nasal

- 2 -

membranes offer advantages over other routes of administration. For example, drugs administered through these membranes have a rapid onset of action, provide therapeutic plasma levels, avoid first pass effect of hepatic metabolism, and avoid exposure of the drug to hostile GI environment. Additional advantages include easy access to the membrane sites so that the drug can be applied, localized and removed easily. Further, there is a good potential for prolonged delivery of large molecules through these membranes.

The oral routes have received far more attention than has the other routes. The sublingual mucosa includes the membrane of ventral surface of the tongue and the floor of the mouth whereas the buccal mucosa constitutes the lining of the cheek. The sublingual mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many drugs. Further, the sublingual mucosa is convenient, acceptable and easily accessible. This route has been investigated clinically for the delivery of a substantial number of drugs.

The ability of molecules to permeate through the oral mucosa appears to be related to molecular size, lipid solubility and peptide protein ionization. Small molecules, less than 1000 daltons appear to cross mucosa rapidly. As molecular size increases, the permeability decreases rapidly. Lipid soluble compounds are more permeable than non-lipid soluble molecules. Maximum absorption occurs when molecules are un-ionized or neutral in electrical charges. Therefore charged molecules present the biggest challenges to absorption through the oral mucosae.

Most proteinic drug molecules are extremely large molecules with molecular weight exceeding 6000 daltons. These large molecules have very poor lipid solubility

- 3 -

and are practically impermeable. Substances that facilitate the absorption or transport of large molecules (>2000 daltons) across biological membranes are known as enhancers, (Lee et al., Critical Reviews in Therapeutic drug Carrier Systems, 8, 91, 1991; Lee et al., Critical Reviews in Therapeutic drug Carrier Systems, 8, 115, 1991, 1992). Enhancers have been characterized as chelators, bile salts, fatty acids, synthetic hydrophilic and hydrophobic compounds, and biodegradable polymeric compounds.

Various mechanisms of action of enhancers have been proposed. These mechanisms of action, at least for protein and peptidic drugs include (1) reducing viscosity and/or elasticity of mucous layer, (2) facilitating transcellular transport by increasing the fluidity of the lipid bilayer of membranes, and (3) increasing the thermodynamic activity of drugs (Critical Rev, 117-125, 1991, 1992).

Many enhancers have been tested so far and some have found to be effective in facilitating mucosal administration of large molecule drugs. However, hardly any penetration enhancing products have reached the market place. Reasons for this include lack of a satisfactory safety profile respecting irritation, lowering of the barrier function, and impairment of the mucocilliary clearance protective mechanism. It has been found that some enhancers, especially those related to bile salts, and some protein solubilizing agents give an extremely bitter and unpleasant taste. This makes their use almost impossible for human consumption on a daily basis. Several approaches have been utilized to improve the taste of the bile salts based delivery systems, but none one of them are commercially acceptable for human oral consumption to date. Among the approaches utilized includes patches for buccal

- 4 -

mucosa, bilayer tablets, controlled release tablets, use of protease inhibitors, buccally administered film patch devices, and various polymer matrices.

The basic problem associated with the above technologies is the use of large quantities of bile acids and their salts to promote the transport of the large molecules through membranes in the form of localized delivery system using patches or tablets. In spite of using protease inhibitors and polymer coatings the technologies failed to deliver proteinic drugs in the required therapeutic concentrations. Further, the problem is compounded because of the localized site effect of the patch which resulted in severe tissue damage in the mouth. Most attempts were made to deliver large molecules via the oral, nasal, rectal, and vaginal routes using single bile acids or enhancing agents in combination with protease inhibitors and biodegradable polymeric materials. However, it is extremely difficult to achieve therapeutic levels of proteinic drugs using these formulations. Single enhancing agents fail to loosen tight cellular junctions in the oral, nasal, rectal and vaginal cavities for a required period of time in order to permit passage of large molecules through the mucosal membranes without further degradation. This problem makes it impractical to use the above mentioned systems commercially.

Oral delivery offers a variety of benefits for systemic drug delivery. For example, it provides easy, non-invasive access to a permeable mucosa, which facilitates rapid drug absorption and a fast onset of action of the drug. In comparison to the GI tract and other organs, the buccal environment has lower enzymatic activity and a neutral pH.

In order to overcome the above mentioned problem of the bitter taste, irritation and the penetration of

- 5 -

large molecules through the sublingual, buccal and GI tract mucosal lining, a system has now been designed where a proteinic drug is encapsulated in mixed micelles made up of a combination of enhancers.

5 A method of substantially overcoming the above disadvantages has now been found. The amount of physiologically peptide or protein in the compositions of the present invention is typically a quantity that provides an effective amount of the pharmaceutical or  
10 drug to produce the physiological activity (therapeutic plasma level) for which peptide or protein is being administered. In consideration of the fact that the bioavailability of any active substance can never be 100%, it is preferable to incorporate slightly larger  
15 amount than the desired dosage.

It is believed that improvements in penetration and absorption of mixed micellar formulations can be achieved by administering the mixed micellar formulation with propellants such as tetrafluoroethane,  
20 heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants. Preferably they are delivered through metered dose spray devices. Metered dose inhalers are known and are a popular  
25 pulmonary drug delivery form for some drugs. The present formulation, including the propellant, is intended to improve the quality of absorption, stability and performance of many formulations. The compositions have been selected to give enhancement in the  
30 penetration through pores, and facilitate absorption of the drugs to reach therapeutic levels in the plasma. One of the other benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self contained.

Summary of the Invention

Accordingly the present invention provides a mixed micellar aerosol pharmaceutical formulation and a propellant, comprising i) a proteinic pharmaceutical agent in micellar form, ii) water, iii) an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 20 wt./wt.% of the total formulation, iv) at least three micelle forming compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, wherein the amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt.% of the formulation, v) a phenolic compound selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and vi) a propellant selected from the group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.

In one embodiment, the alkali metal C8 to C22 alkyl sulphate is in a concentration of from 2 to 5 wt./wt.% of the total formulation.



- 7 -

In another embodiment, the alkali metal C8 to C22 alkyl sulphate is sodium lauryl sulphate.

In another embodiment, the lecithin is saturated or unsaturated, preferably selected from the group  
5 consisting of phosphatidylcholine, phosphatidyl serine, sphingomyelin, phosphatidylethanolamine, cephalin, and lysolecithin.

In yet another embodiment, at least one of the micelle forming compounds is selected from the group  
10 consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, polidocanol alkyl ethers, trihydroxy oxo cholanyl glycine, polyoxyethylene ethers, triolein and mixtures thereof, the concentration such micelle forming compound being from about 1 to  
15 about 5 wt./wt.%.  
20

Preferably, the ratio of proteinic pharmaceutical agent, e.g. insulin, to propellant is from 5:95 to 25:75.

In another embodiment, the propellant is selected  
20 from the group consisting of tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.

In yet another embodiment, the mixed micellar  
25 pharmaceutical formulation and propellant are contained in an aerosol dispenser.

For insulin-containing and some other compositions, the composition may also contains at least one inorganic salt which opens channels in the gastrointestinal tract  
30 and may provide additional stimulation to release insulin. Non-limiting examples of inorganic salts are sodium, potassium, calcium and zinc salts, especially sodium chloride, potassium chloride, calcium chloride, zinc chloride and sodium bicarbonate.

35 It will be recognized by those skilled in the art

that for many pharmaceutical compositions it is usual to add at least one antioxidant to prevent degradation and oxidation of the pharmaceutically active ingredients. It will also be understood by those skilled in the art 5 that colorants, flavouring agents and non-therapeutic amounts of other compounds may be included in the formulation. Typical flavouring agents are menthol, sorbitol and fruit flavours.

In one embodiment the antioxidant is selected from 10 the group consisting of tocopherol, deteroxime mesylate, methyl paraben, ethyl paraben, ascorbic acid and mixtures thereof. A preferred antioxidant is tocopherol.

In a preferred embodiment at least one protease 15 inhibitor is added to the formulation to inhibit degradation of the pharmaceutical agent by the action of proteolytic enzymes. Of the known protease inhibitors, most are effective at concentrations of from 1 to 3 wt./wt.% of the formulation.

20 Non-limiting examples of effective protease inhibitors are bacitracin, soyabean trypsin, aprotinin and bacitracin derivatives, e.g. bacitracin methylene disalicylate. Bacitracin is the most effective of those named when used in concentrations of from 1.5 to 25 2 wt./wt.%. Soyabean trypsin and aprotinin also may be used in concentrations of about 1 to 2 wt./wt.% of the formulation.

The proteinic pharmaceutical agent may be selected from a wide variety of macromolecular agents, depending 30 on the disorder to be treated, generally with molecular weights greater than about 1000 and especially between about 1000 and 2 000 000. Preferred pharmaceutical agents are selected from the group consisting of insulin, heparin, low molecular weight heparin, hirulog, 35 hirugen, hiridine, interferons, interleukins, cytokines,

- 9 -

mono and polyclonal antibodies, immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, insulin like growth factors (IGF), glucagon like peptides (GLP-1),  
5 large molecule antibiotics, protein based thrombolytic compounds, platelet inhibitors, DNA, RNA, gene therapeutics, antisense oligonucleotides, opioids, narcotics, hypnotics, steroids and pain killers.

The present invention also provides a process for  
10 making a pharmaceutical composition suitable for delivery through transdermal membranes comprising the steps of:

a) mixing a proteinic pharmaceutical agent composition in an aqueous medium with an alkali metal C8  
15 to C22 alkyl sulphate, and at least three micelle forming compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid,  
20 linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein,  
25 polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, to form a micellar proteinic pharmaceutical agent composition;

30 b) adding a phenolic compound selected from the group consisting of phenol, m-cresol and mixtures thereof, in which the addition takes place at a time selected from the group consisting of before the addition of the alkali metal C8 to C22 alkyl sulphate,  
35 during the addition of the alkali metal C8 to C22 alkyl

- 10 -

5 sulphate, after the addition of the alkali metal C8 to C22 alkyl sulphate, before the addition of at least one of the micelle forming compounds, during the addition of at least one of the micelle forming compounds and after the addition of at least one of the micelle forming compounds; and subsequently

d) placing the formulation into an aerosol dispenser and charging the dispenser a propellant;

wherein the composition has at least three micelle forming compounds and the amount of the micelle forming compounds are each present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of alkali metal alkyl sulphate and micelle forming compounds is less than 50 wt./wt.% of the formulation.

In one embodiment, the process comprises:

a) mixing a proteinic pharmaceutical agent composition in an aqueous medium with an alkali metal C8 to C22 alkyl sulphate, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, to form a micellar proteinic pharmaceutical agent composition;

b) during step a) or after step a), adding at least one micelle forming compound, different from that added in step a);

- 11 -

c) during step a) or after step a), adding a phenolic compound selected from the group consisting of phenol, m-cresol and mixtures thereof; and subsequently

d) placing the formulation into an aerosol dispenser and charging the dispenser a propellant;

wherein the composition has at least three micelle forming compounds and the amount of the micelle forming compounds are each present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of alkali metal alkyl sulphate and micelle forming compounds is less than 50 wt./wt.% of the formulation.

In another embodiment, the process comprises:

a') mixing the proteinic pharmaceutical agent composition in an aqueous medium with the alkali metal C8 to C22 alkyl sulphate and optionally at least one of the micelle forming compounds, to form a micellar proteinic pharmaceutical agent composition;

b') slowly adding at least one of the micelle forming compounds, different from that added in step a'), while mixing vigorously, to form a mixed micellar composition;

c') mixing the mixed micellar composition resulting from steps a') and b') with the phenolic compound; and subsequently

d') placing the formulation into an aerosol dispenser and charging the dispenser a propellant.

In a further embodiment, the process comprises the steps of:

a") mixing the proteinic pharmaceutical agent composition in an aqueous medium with the alkali metal C8 to C22 alkyl sulphate and optionally at least one of the micelle forming compounds, while mixing vigorously, to form a mixed micellar composition;

b") mixing the mixed micellar composition

- 12 -

resulting from step a") with the phenolic compound; and subsequently

c") placing the formulation into an aerosol dispenser and charging the dispenser a propellant.

5 In another embodiment, the alkali metal alkyl sulphate is sodium lauryl sulphate.

In yet another embodiment, the formulation has micelle forming compound combinations selected from the group consisting of sodium hyaluronate, monoolein and  
10 saturated phospholipid, ii) saturated phospholipid, monoolein and glycolic acid, iii) sodium hyaluronate, polyoxyethylene ether and lecithin, iv) polyoxyethylene ether, trihydroxy oxo cholanyl and lecithin, v)  
polidocanol 9 lauryl ether, polylysine and triolein, vi)  
15 saturated phospholipid, polyoxyethylene ether and glycolic acid, and vii) trihydroxy oxo-cholanyl glycine, lecithin and chenodeoxycholate.

The vigorous mixing may be accomplished by using high speed stirrers, e.g. magnetic stirrers or propellor  
20 stirrers, or by sonication.

In one embodiment, the mixed micellar formulation is formed by sonication of the aqueous micellar pharmaceutical agent composition in which one of the micelle forming compounds is lecithin.

25 The present invention also provides a metered dose aerosol dispenser with the composition of the present invention therein, in which an aqueous solution containing the proteinic pharmaceutical agent, and the propellant, are in a single phase.

30 The present invention also provides a method for administering mixed micellar pharmaceutical formulations of the present invention, by spraying the intermixed composition into the mouth with a metered dose spray device.

35 The present invention also provides a method for

- 13 -

administration of a proteinic pharmaceutical agent in a buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar pharmaceutical formulation and a propellant comprising:

- i) the proteinic pharmaceutical agent in micellar form, ii) water, iii) an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 20 wt./wt.% of the total formulation, iv) at least three micelle forming compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof,
- 20 polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, wherein the amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt.% of the formulation, v) a phenolic compound selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and vi) a propellant selected from the group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.

35 In one embodiment, the dispenser is first shaken

- 14 -

prior to spraying the pharmaceutical formulation and propellant into the buccal cavity.

Detailed Description of Preferred Embodiments

The present invention provides an improved method  
5 for delivery of macromolecular (high molecular weight)  
pharmaceutical agents, particularly through the  
membranes in the mouth or lungs. The pharmaceutical  
agents cover a wide spectrum of agents, including  
proteins, peptides, hormones, vaccines and drugs. The  
10 molecular weights of the macromolecular pharmaceutical  
agents are preferably above 1000, especially between  
1000 and 2 000 000.

For example, hormones which may be administered  
with the present invention include thyroids, androgens,  
15 estrogens, prostaglandins, somatotropins, gonadotropins,  
erythropoetin, interferons, interleukins, steroids and  
cytokines. Vaccines which may be administered with the  
present invention include bacterial and viral vaccines  
such as vaccines for hepatitis, influenza, tuberculosis,  
20 canary pox, chicken pox, measles, mumps, rubella,  
pneumonia, BCG, HIV and AIDS. Bacterial toxoids which  
may be administered using the present invention include  
diphtheria, tetanus, pseudomonas and mycobacterium  
tuberculosis. Examples of specific cardiovascular or  
25 thrombolytic agents include heparin, hirugen, hirulos  
and hirudine. Large molecules usefully administered  
with the present invention include monoclonal  
antibodies, polyclonal antibodies and immunoglobins.

As will be understood, the concentration of the  
30 pharmaceutical agent is an amount sufficient to be  
effective in treating or preventing a disorder or to  
regulate a physiological condition in an animal or  
human. The concentration or amount of pharmaceutical  
agent administered will depend on the parameters  
35 determined for the agent and the method of



- 15 -

administration, e.g. nasal, buccal, pulmonary. For example, nasal formulations tend to require much lower concentrations of some ingredients in order to avoid irritation or burning of the nasal passages. It is  
5 sometimes desirable to dilute an oral formulation up to 10-100 times in order to provide a suitable nasal formulation.

The mixed micellar formulation may be prepared by mixing an aqueous solution of the pharmaceutical agent,  
10 the alkali metal C8 to C22 alkyl sulphate, at least three micelle forming compounds, and optionally the phenolic compound. The micelle forming compounds may be added at the same time or after addition of the alkali metal alkyl sulphate. Mixed micelles will form with  
15 substantially any kind of mixing of the ingredients but vigorous mixing is preferred in order to provide smaller size micelles.

In one method a first micellar composition is prepared which contains the pharmaceutically active  
20 agent and at least the alkali metal alkyl sulphate. The first micellar composition is then mixed with at least three micelle forming compounds to form a mixed micellar composition. In another method, the micellar composition is prepared by mixing the pharmaceutically  
25 active agent, the alkali metal alkyl sulphate and at least one of the micelle forming compounds, followed by addition of the remaining micelle forming compounds, with vigorous mixing.

The phenol and/or m-cresol may be added to the  
30 mixed micellar composition to stabilize the formulation and protect against bacterial growth. Alternatively, the phenol and/or m-cresol may be added with the micelle forming ingredients. An isotonic agent such as glycerin may also be added after formation of the mixed micellar  
35 composition. The formulation is then put into an

- 16 -

aerosol dispenser and the dispenser charged with the propellant. The propellant, which is under pressure, is in liquid form in the dispenser. In the present invention, when the composition of the present invention is in a dispenser, the aqueous phase may be separated from the propellant phase. Preferably, however, the ratios of the ingredients are adjusted by simple experimentation so that the aqueous and propellant phases become one, i.e. there is one phase. If there are two phases, it is necessary to shake the dispenser prior to dispensing a portion of the contents, e.g. through a metered valve. The dispensed dose of pharmaceutical agent is propelled from the metered valve in a fine spray.

The preferred propellants are hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. Even more preferred is HFA 134a (1,1,1,2 tetrafluoroethane).

Although the present invention has such wide applicability, the invention is described hereinafter with particular reference to insulin and its analogues, which are used for the treatment of diabetes.

As indicated hereinbefore, the aerosol compositions of the present invention require that the pharmaceutical formulation be in mixed micellar form.

In the case of insulin, which is intended for administration through the mouth cavity, the first micellar solution may be made by adding water, and then hydrochloric acid (typically 5M) to powdered insulin, and then stirring until the powder is dissolved and a clear solution is obtained. The solution is then neutralized with sodium hydroxide. The sodium alkyl sulphate may then be added with low speed stirring, either alone or with at least one micelle forming compound. A typical concentration of sodium lauryl

- 17 -

sulphate, as the sodium alkyl sulphate, in the aqueous solution is about 3 to 20 wt./wt.% of the solution. Typically, insulin is present in the micellar solution in an amount which will give a concentration of about 2 to 4 wt./wt.% of the final formulation.

The micellar solution so formed may then be mixed vigorously, e.g. by sonication or high speed stirring, to form a mixed micelle liposomal solution. Other micelle forming compounds may then be added. For example, one or more micelle forming compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, and deoxycholate may be added. The mixing may be done with a high speed mixer or sonicator to ensure uniform micelle particle size distribution within the formulation.

After forming the mixed micellar formulation, the phenol and/or m-cresol is added prior to charging the composition to an aerosol dispenser. As indicated above, other ingredients, such as isotonic agents, flavouring agents, anti-oxidants, salts, protease inhibitors or other pharmaceutically acceptable compounds may also be added. After the formulation is in the aerosol dispenser, the dispenser is charged with propellant in a known manner.

Each of the micelle forming compounds, when present, is in a concentration of from 1 to 20 wt./wt.%

- 18 -

of the total formulation.

Preferred salts of hyaluronic acid are alkali metal hyaluronates, alkaline earth hyaluronates and aluminium hyaluronate. The preferred salt is sodium hyaluronate.

5 The preferred concentration of hyaluronic acid or pharmaceutically acceptable salts of hyaluronic acid is from 1 to 5 wt./wt.% of the total formulation. An even more preferred range is from 1.5 to 3.5 wt./wt.% of the total formulation.

10 The specific concentrations of the essential ingredients can be determined by relatively straightforward experimentation. It will be understood that the amounts of certain ingredients may need to be limited in order to avoid compositions which produce  
15 foam when sprayed rather than forming a fine spray. For absorption through the oral cavities, it is often desirable to increase, e.g. double or triple, the dosage which is normally required through injection or administration through the gastrointestinal tract.

20 As will be understood, the amount of each component of the formulation will vary depending on the pharmaceutical agent and the site of application. Preferred formulations buccal application have the following combinations: i) sodium lauryl sulphate,  
25 polidocanol 10 lauryl ether, sodium oxo cholanyl glycine and lecithin; ii) sodium lauryl sulphate, polidocanol 10 lauryl ether, phosphatidyl choline, oleic acid; iii) sodium lauryl sulphate, polidocanol 10 lauryl ether, sodium hyaluronate and lecithin; iv) sodium lauryl  
30 sulphate, polidocanol 9 lauryl ether, triolein and polylysine; v) sodium lauryl sulphate, polyoxyethylene ether (10 lauryl), trihydroxy oxo cholanyl glycine and lecithin, vi) sodium lauryl sulphate, polidocanol 20 lauryl ether, evening of primrose oil and lecithin and  
35 vii) sodium lauryl sulphate, trihydroxy oxo-cholanyl

- 19 -

glycine, lecithin and chenodeoxycholate.

The therapeutic compositions of the present invention may be stored at room temperature or at cold temperature. Storage of proteinic drugs is preferable  
5 at a cold temperature to prevent degradation of the drugs and to extend their shelf life.

It is believed that the mixed micelles of the present invention encapsulate molecules with a high degree of efficiency (>90% encapsulation). In general  
10 the size of the micelle particles in the mixed micellar composition is about 1 to 10 nm or less, and preferably from 1 to 5 nm. Such mixed micelles tend to be smaller than the pores of the membranes in the oral cavity or the GI tract. It is therefore believed that the  
15 extremely small size of mixed micelles helps the encapsulated molecules penetrate efficiently through the mucosal membranes of the oral cavity.

The desired size of aerosol droplets which are sprayed from the aerosol dispenser will depend, in part,  
20 on where the pharmaceutical is to be deposited. For example, for deposition in the lungs, particle sizes of less than about 5  $\mu\text{m}$  are preferred whereas for absorption in the buccal cavity of the mouth, particle sizes of about 6-10  $\mu\text{m}$  are preferred.

25 The amount of physiologically peptide or protein in the compositions of this invention is typically a quantity that provides an effective amount of the pharmaceutical or drug to produce the physiological activity (therapeutic plasma level) for which peptide or  
30 protein is being administered. In consideration of the fact that the bioavailability of any active substance can never be 100%, that is to say the administered dose of the active drug is not completely absorbed, it is preferable to incorporate slightly larger amount than  
35 the desired dosage.

- 20 -

It is believed that improvements in penetration and absorption of mixed micellar formulations are achieved by mixing the mixed micellar formulation with propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants. Preferably they are delivered through metered dose spray devices. Metered dose inhalers are known and are a popular pulmonary drug delivery form for some drugs. One of the benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self contained.

As indicated hereinbefore, by making adjustments to the concentrations of ingredients in the formulation, the formulation in the aerosol container may be in a single phase, i.e. the propellant and the remainder of the formulation are intimately mixed together. In such instances, the single phase generally remains stable for many months. With other combinations the formulation may be in two phases, i.e. the propellant in one phase and the remainder in another phase. In such event, then the formulation should be shaken vigorously prior to spraying the formulation into the mouth, so that there is a uniform amount of pharmaceutical agent in each shot delivered from the metered dose applicator (aerosol container).

The present formulation, including the propellant, is intended to improve the quality of absorption, stability and performance of many formulations. The compositions have been selected to give enhancement in the penetration through pores, and facilitate absorption of the drugs to reach therapeutic levels in the plasma.

Administration of the formulation into the buccal cavity is by spraying the formulation into the mouth,

- 21 -

without inhalation, so that the droplets stay in the mouth rather than be drawn into the lungs.

The invention is illustrated by reference to the following examples.

5 Example 1

A first experiment was conducted to provide data for comparative purposes. This example does not fall within the scope of the present invention.

Powdered insulin was placed in a glass beaker  
10 equipped with a stirrer. Distilled water was added and the solution was stirred at low speed. To this solution was added 5M HCl (pH 2) solution dropwise until the insulin was solubilized completely. This solution was then neutralized with 5M NaOH solution dropwise until  
15 the pH was between 7 and 8. Seven mg phenol and 7 mg m-cresol were added to the solution and mixed thoroughly. The solution was diluted with distilled water until there were 200 units insulin per millilitre of solution. One millilitre portions were then transferred to glass  
20 vials, which were then charged with 10.8 g HFA 134a propellant using a Pamasol (trade mark) 2008 semi-automatic gas filling apparatus.

Ten diabetic volunteers were asked to fast overnight and not have any breakfast prior to dosing.  
25 On the first day, the volunteers were given 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the volunteers were given 60 units insulin of this example (10 puffs of 6 units each) into the mouth, without  
30 inhalation. Blood glucose levels were monitored at intervals using Bayer's glucometer Elite for 3 hours. The average results, in millimoles per litre, are shown in Table I.

- 22 -

Table I

Time*:	0	15	30	60	90	120	150	180
Injection:	6.8	6.6	5.9	5.3	4.9	4.5	4.1	3.7
Spray:	6.3	6.8	6.2	6.8	6.1	6.7	6.5	6.2

5 \* time in minutes

These tests indicate that compared to the injection method, the spray method with formulations without the alkali metal alkyl sulphate and absorption enhancers of the present invention failed to lower the blood glucose  
10 levels in diabetic patients. Thus, combination of the formulation and the spray method of application had no metabolic effect.

Example 2

Powdered insulin was placed in a glass beaker  
15 equipped with a stirrer. Distilled water was added and the solution was stirred at low speed. To this solution was added 5M HCl (pH 2) solution dropwise until the insulin was solubilized completely. This solution was then neutralized, while stirring slowly, with 5M NaOH  
20 solution dropwise until the pH was between 7 and 8. To this solution was added 7 mg sodium lauryl sulphate, 7 mg polyoxyethylene ether (10 lauryl) and 7 mg trihydroxy oxo cholanyl glycine and dissolved completely. Seven mg lecithin, solubilized in a water  
25 alcohol solution (7 mg/mL) was then added while stirring at high speed, i.e. 2000 rpm. The solution was stirred for 30 minutes and then stored at 10°C. The resulting mixed micellar solution had about 200 units insulin. To this mixture 5 mg phenol, 5 mg m-cresol and 10 mg  
30 glycerin were added.

The solution was pipetted (1mL/vial) into 10 mL capacity glass vials. The vials were then charged with HFA 134a propellant with a Pamasol 2008 automatic gas filling apparatus. The amount of propellant was  
35 adjusted to 9 mL shot size in order to deliver 2 units



- 23 -

insulin per actuation of the aerosol vial. The valves of the vials were designed to deliver 100  $\mu$ L spray per actuation, containing 2 units insulin. The formulation, in the glass vial, including the propellant, was in a single phase, i.e. was homogeneous.

The aerodynamic particle size was determined by an 8-stage USP Anderson (trade mark) Cascade Impactor Mark II. The impactor was cleaned with methanol and air dried at 30°C. Glass fibre filters were placed on the collection plates. The actuator was attached to the mouthpiece of the impactor and assembled onto the USP induction port and jet stages. A vacuum pump was connected and the air flow rate set to 28.3 litres per minute. The vial was primed by shaking for 10 seconds and actuating twice to waste. The shot was delivered by discharging the actuator into the mouthpiece and repeating 25 times. The deposited insulin was collected by rinsing the mouthpiece with 0.6 mL EDTA in 10 mL water at pH 8.7. The filters were removed and placed in scintillation vials and sonicated for 15 minutes. The quantity of insulin was then analysed using RP-HPLC. The results are shown in Table II (2 units per actuation) and III (4 units per actuation).

Table II

25	Stage No.	0	1	2	3
	Volume (mL)	10	10	10	10
	Mass (mg)	0.79	0.81	0.78	*
	Units	10.4	10.0	10.0	
	Actuation	5	5	5	
30	Units per actuation	2.0	2.0	2.1	
	Particle size ( $\mu$ m)	8.8	5.8	5.7	

\* not determined/detected

- 24 -

Table III

Stage No.	0	1	2	3
Volume (mL)	10	10	10	10
Mass (mg)	0.79	0.81	0.78	**
5 Units	20.7	21.0	20.1	
Actuation	5	5	5	
Units per				
actuation	4.15	4.18	4.01	
Particle size ( $\mu\text{m}$ )	9	5.8	4.7	

10 \*\* not determined

Based on these tests, the particle size was determined to be about 7  $\mu\text{m}$ , and stages 3-8 showed no insulin deposition, indicating that most particles were larger than about 6  $\mu\text{m}$ . This suggests that there would  
 15 be no deep lung deposition of the formulation and that most of the formulation would be deposited in the buccal cavity.

Further tests were conducted to determine the shot size accuracy, by firing shots into thiel tubes and  
 20 weighing the tubes before and after the sample collection. The tests showed the shots for 2 units per actuation weighed between 0.075 and 0.083 grams, i.e. within about  $\pm 5\%$ . The tests showed the shots for 4 units per actuation weighed between 0.076 and  
 25 0.083 grams, i.e. within about  $\pm 5\%$ . The tests showed the shots for 6 units per actuation weighed between 0.070 and 0.082 grams, i.e. within about  $\pm 8\%$ . HPLC analysis showed the doses delivered to be from 2.01 units to 2.07 units for 2 units per actuation; from 3.9 units to 4.4  
 30 units for 4 units per actuation, and from 5.8 units to 6.3 units for 6 units per actuation.

Ten diabetic volunteers were asked to fast overnight and not have any breakfast prior to dosing. On the first day, the volunteers were given 10 units  
 35 insulin by injection (regular fast acting insulin,

- 25 -

available from Eli Lilly). On the second day, the volunteers were given 60 units insulin of this example (10 puffs of 6 units each) into the mouth, without inhalation. Plasma insulin levels were measured at intervals by the RIA method for 3 hours. The average results, in micromoles per millilitre, are shown in Table IV. Blood glucose levels were also monitored at intervals using Bayer's glucometer Elite for 3 hours. The average results, in millimoles per litre, are shown in Table V.

Table IV

Time*:	0	15	30	45	60	90	120	150	180
Injection:	10	9.1	11	16	31	45	32	25	20
Spray:	8.7	12.1	19.8	28	27	36	29	21	13

\* time in minutes

This test indicated that the injection method and spray method were comparable.

Table V

Time*:	0	15	30	45	60	90	120	150	180
Injection:	6.1	6.0	5.9	5.5	5.1	4.5	3.8	4.2	4.4
Spray:	6.6	6.3	5.8	5.2	4.8	4.9	4.5	5.0	5.3

\* time in minutes

This test indicated that the injection method and spray method were comparable in terms of glucose level.

Tests were also conducted with 40 units of spray at 10 puffs each, and compared to 10 units injected by measuring plasma levels and glucose levels as above. The results are shown in Table VI (plasma) and VII (glucose).

Table VI

Time*:	0	15	30	45	60	90	120	150	180
Injection:	9	9	13	19	34	45	42	35	24
Spray:	10	13	18.5	27	30	33	29	19	14

\* time in minutes

This test indicated that the injection method and

- 26 -

spray method were comparable in terms of plasma insulin levels.

Table VII

Time*:	0	15	30	60	90	120	150	180
5 Injection:	5.8	6.0	5.9	5.5	5.0	4.5	4.1	3.9
Spray:	6.0	5.7	5.4	5.0	5.1	4.7	4.5	4.2

\* time in minutes

This test indicated that the injection method and spray method were comparable in terms of glucose levels.

#### 10 Example 3

Powdered insulin was placed in a glass beaker equipped with a stirrer. Distilled water was added and the solution was stirred at low speed. To this solution was added 5M HCl (pH 2) solution dropwise until the

15 insulin was solubilized completely. This solution was then neutralized, while stirring slowly, with 5M NaOH solution dropwise until the pH was between 7 and 8. To this solution was added 30.4 mg sodium lauryl sulphate per millilitre of insulin solution, 30.4 mg polidocanol

20 9 lauryl ether per millilitre of insulin solution and 10.0 mg polylysine per millilitre of insulin solution, and dissolved completely. 15.2 mg triolein per millilitre of insulin solution was then added while stirring at high speed, i.e. 2000 rpm. The solution was

25 stirred for 30 minutes and then stored at 10°C. The resulting solution was a mixed micellar solution. To this mixture 15.2 mg m-cresol per millilitre of insulin solution were added.

The solution was pipetted (1 mL) into glass vials.

30 The vials were then charged with 10.8 g HFA 134a propellant per vial, with a Pamasol 2008 automatic gas filling apparatus. The valves of the vials were designed to deliver 100  $\mu$ L spray per actuation, containing 6 units insulin. The formulation, in the

35 glass vial, including the propellant, was in a single

- 27 -

phase, i.e. was homogeneous.

Ten diabetic volunteers were asked to fast overnight and not have any breakfast prior to dosing. On the first day, the volunteers were given 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the volunteers were given 60 units insulin of this example (10 puffs of 6 units each) into the mouth, without inhalation. Plasma insulin levels were measured at intervals by the RIA method for 3 hours. The average results, in micromoles per millilitre, are shown in Table VIII. Blood glucose levels were also monitored at intervals using Bayer's glucometer Elite for 3 hours. The average results, in millimoles per litre, are shown in Table IX.

Table VIII

Time*:	0	15	30	45	60	90	120	150	180
Injection:	9	9.1	14	20	40	48	39	34	27
Spray:	10	15.1	22	32	47	36	27	21	19

\* time in minutes

This test indicated that the injection method and spray method were comparable.

Table IX

Time*:	0	15	30	45	60	90	120	150	180
Injection:	6.6	6.5	6.1	5.5	4.9	4.5	3.8	3.5	4.4
Spray:	6.8	5.9	5.2	4.8	4.3	3.9	4.5	5.7	5.3

\* time in minutes

This test indicated that the injection method and spray method were comparable in terms of glucose level.

#### 30 Example 4

A further experiment was conducted to provide data for comparative purposes.

Powdered insulin was placed in a glass beaker equipped with a stirrer. Distilled water was added and the solution was stirred at low speed. To this solution

- 28 -

was added 5M HCl (pH 2) solution dropwise until the insulin was solubilized completely. This solution was then neutralized with 5M NaOH solution dropwise until the pH was between 7 and 8. The solution was diluted  
5 with distilled water until there were 600 units insulin per millilitre of solution. One millilitre portions were then transferred to 10 mL capacity glass vials, which were then charged with 10.8 g HFA 134a propellant using a Pamasol (trade mark) 2008 semi-automatic gas  
10 filling apparatus. This formulation does not fall within the scope of the present invention.

The gas phase and the aqueous phase were observed to be distinctly separate. Even shaking of the vials did not appear to homogenize the composition.

15 Tests were conducted to determine the shot size accuracy, by firing shots into thiel tubes and weighing the tubes before and after the sample collection. The tests showed five consecutive shots for 6 units per actuation weighed 0.094, 0.110, 0.200, 0.150 and  
20 0.050 grams, i.e. within about  $\pm 60\%$  of the average. This compares with  $\pm 8\%$  in Example 2 (which is within the scope of the present invention).

HPLC analysis showed the average doses delivered to be 5.4 units per actuation from shots 5-10, 7.1 units  
25 per actuation from shots 45-50 and 8.6 units per actuation from shots 85-90.

These results showed that such composition, without the micelle-forming ingredients, gave non-uniform dose delivery.

30 Example V

Ten millilitres of concentrated insulin containing 10 000 units per millilitre was placed in a glass beaker. To this solution was added 7 mg sodium lauryl sulphate, 7 mg polyoxyethylene ether (10 lauryl), 7 mg trihydroxy  
35 oxo-cholanyl glycine and 7 mg lecithin. The components

- 29 -

were stirred until they were completely dissolved. Seven mg phenol and 7 mg m-cresol were added to the solution and mixed thoroughly.

One millilitre portions of the solution were  
 5 pipetted into 10 mL capacity glass vials. The vials had metered dose valves thereon. The vials were then charged with HFA 134a propellant with Pamasol 2008 (trade mark) gas filling apparatus. The amount of propellant was adjusted to 9 mL per vial in order to  
 10 deliver 10 units of insulin per actuation of the valve (100  $\mu$ L shot/actuation). The formulation, in the glass vial, including the propellant, was in a single phase, i.e. was homogeneous.

Ten diabetic patients fasted overnight and did not  
 15 have a breakfast prior to dosing. On the first day, each patient had 7 units regular fast acting insulin, available from Eli Lilly, administered by injection. On the second day, each patient was given 70 units insulin of this example (7 puffs of 10 units each) into the  
 20 mouth, without inhalation. Blood samples were collected and plasma glucose levels were measured at intervals using Bayer's glucometer Elite for 3 hours. The average results, in millimoles per millilitre, are shown in Table X. Insulin levels were also monitored at  
 25 intervals by the RIA method for 3 hours. The average results, in micromoles per litre, are shown in Table XI.

Table X

Time*:	0	15	30	45	60	90	120	150	180
Injection:	6.5	6.3	5.7	5.2	4.8	4.9	3.8	4.5	4.7
30 Spray:	6.1	6.0	6.0	5.9	5.5	4.5	3.6	4.1	4.4

Table XI

Time*:	0	15	30	45	60	90	120	150	180
Injection:	8.7	12.1	19.8	29.0	36.0	37.0	33.0	23.0	14.0
Spray:	9.1	11.0	16.0	31.0	45.0	43.0	45.0	32.0	22.0

35 \* time in minutes

- 30 -

These tests indicated that the injection method and spray method were comparable.

Example VI

Ten millilitres of concentrated insulin containing  
5 10 000 units per millilitre was placed in a glass beaker.  
To this solution was added 15 mg sodium lauryl sulphate,  
15 mg chenodeoxycholate, 15 mg trihydroxy oxo-cholanyl  
glycine and 7 mg lecithin. The components were stirred  
until they were completely dissolved. Seven mg phenol  
10 and 7 mg m-cresol were added to the solution and mixed  
thoroughly.

One millilitre portions of the solution were  
pipetted into 10 mL capacity glass vials. The vials had  
metered dose valves thereon. The vials were then  
15 charged with HFA 134a propellant with Pamasol 2008  
(trade mark) gas filling apparatus. The amount of  
propellant was adjusted to 9 mL per vial in order to  
deliver 10 units of insulin per actuation of the valve  
(100  $\mu$ L shot/actuation). The formulation, in the glass  
20 vial, including the propellant, was in a single phase,  
i.e. was homogeneous.

Ten diabetic patients fasted overnight and did not  
have a breakfast prior to dosing. On the first day,  
each patient had 7 units regular fast acting insulin,  
25 available from Eli Lilly, administered by injection.  
Fifteen minutes after administering the insulin, each  
patient was given a 250 calorie Sustacal (trade mark)  
drink, which was drunk within 10 minutes. On the second  
day, each patient was given 70 units insulin of this  
30 example (7 puffs of 10 units each) into the mouth,  
without inhalation. Fifteen minutes after administering  
the insulin, each patient was given a 250 calorie  
Sustacal (trade mark) drink, which was drunk within 10  
minutes. Blood samples were collected and plasma  
35 glucose levels were measured at intervals, using Bayer's



- 31 -

glucometer Elite for 4 hours. The average results, in millimoles per millilitre, are shown in Table XII.

Table XII

Time*:	0	15	30	60	90	120	180	240
5 Injection:	9.2	9.0	9.5	12.3	12.4	12.6	11.3	9.7
Spray:	8.8	8.8	8.7	10.4	12.0	12.4	11.9	10.5

\* time in minutes

These tests indicated that the injection method and spray method were comparable.

- 32 -

CLAIMS:

1. A mixed micellar aerosol pharmaceutical formulation and a propellant, comprising i) a proteinic pharmaceutical agent in micellar form, ii) water, iii) an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 20 wt./wt.% of the total formulation, iv) at least three micelle forming compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, wherein the amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt.% of the formulation, v) a phenolic compound selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and vi) a propellant selected from the group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.
2. A formulation according to Claim 1 wherein the alkali metal C8 to C22 alkyl sulphate is in a concentration of from 2 to 5 wt./wt.% of the total

- 33 -

formulation..

3. A formulation according to Claim 1 wherein the alkali metal C8 to C22 alkyl sulphate is sodium lauryl sulphate.
- 5 4. A formulation according to Claim 2 wherein the alkali metal C8 to C22 alkyl sulphate is sodium lauryl sulphate.
5. A formulation according to Claim 1 wherein the lecithin selected from the group consisting of saturated  
10 phosphatidylcholine, unsaturated phosphatidylcholine, phosphatidyl serine, sphingomyelin, phosphatidylethanolamine, cephalin, and lysolecithin.
6. A formulation according to Claim 1 wherein one of the micelle forming compounds is selected from the group  
15 consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, polidocanol alkyl ethers, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, polyoxyethylene ethers and analogues thereof,  
20 chenodeoxycholate, and mixtures thereof, the concentration such micelle forming compound being from about 1 to about 5 wt./wt.%.  
7. A formulation according to Claim 1 wherein the propellant is selected from the group consisting of  
25 tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.
8. A formulation according to Claim 2 wherein the propellant is selected from the group consisting of  
30 tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.
9. A formulation according to Claim 1 wherein the formulation comprises combinations selected from the  
35 group consisting of i) sodium lauryl sulphate,

- 34 -

polidocanol 10 lauryl ether, sodium oxo cholanyl glycine and lecithin; ii) sodium lauryl sulphate, polidocanol 10 lauryl ether, phosphatidyl choline, oleic acid; iii) sodium lauryl sulphate, polidocanol 10 lauryl ether, 5 sodium hyaluronate and lecithin; iv) sodium lauryl sulphate, polidocanol 9 lauryl ether, triolein and polylysine; v) sodium lauryl sulphate, polyoxyethylene ether (10 lauryl), trihydroxy oxo cholanyl glycine and lecithin, vi) sodium lauryl sulphate, polidocanol 20 10 lauryl ether, evening of primrose oil and lecithin, and vii) sodium lauryl sulphate, trihydroxy oxo-cholanyl glycine, lecithin and chenodeoxycholate.

10. A formulation according to Claim 1 wherein the pharmaceutical agents are selected from the group 15 consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, interleukins, cytokines, mono and polyclonal antibodies, immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, 20 insulin like growth factors (IGF), glucagon like peptides (GLP-1), large molecule antibiotics, protein based thrombolytic compounds, platelet inhibitors, DNA, RNA, gene therapeutics, antisense oligonucleotides, opioids, narcotics, hypnotics, steroids and pain 25 killers.

11. A formulation according to Claim 2 wherein the pharmaceutical agent is insulin.

12. A formulation according to Claim 1 wherein the ratio of proteinic pharmaceutical agent to propellant is 30 from 5:95 to 25:75.

13. A formulation according to Claim 1 which is contained in a metered dose device.

14. A process for making a pharmaceutical composition suitable for delivery through transdermal membranes 35 comprising the steps of:

- 35 -

mixing a proteinic pharmaceutical agent composition in an aqueous medium with an alkali metal C8 to C22 alkyl sulphate, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, to form a micellar proteinic pharmaceutical agent composition; and a phenolic compound selected from the group consisting of phenol, m-cresol and mixtures thereof; and subsequently

b) placing the formulation into an aerosol dispenser and charging the dispenser a propellant; wherein the composition has at least three micelle forming compounds and the amount of the micelle forming compounds are each present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of alkali metal alkyl sulphate and micelle forming compounds is less than 50 wt./wt.% of the formulation.

15. A process according to Claim 14 comprising the steps of:

a) mixing a proteinic pharmaceutical agent composition in an aqueous medium with an alkali metal C8 to C22 alkyl sulphate, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile

- 36 -

extract, cucumber extract, oleic acid, linoleic acid,  
linolenic acid, monoolein, monooleates, monolaurates,  
borage oil, evening of primrose oil, menthol, trihydroxy  
oxo cholanyl glycine and pharmaceutically acceptable  
5 salts thereof, glycerin, polyglycerin, lysine,  
polylysine, triolein, polyoxyethylene ethers and  
analogues thereof, polidocanol alkyl ethers and  
analogues thereof, chenodeoxycholate, deoxycholate, and  
mixtures thereof, to form a micellar proteinic  
10 pharmaceutical agent composition;

b) during step a) or after step a), adding at least  
one micelle forming compound, different from that added  
in step a);

c) during step a) or after step a), adding a  
15 phenolic compound selected from the group consisting of  
phenol, m-cresol and mixtures thereof; and subsequently

d) placing the formulation into an aerosol  
dispenser and charging the dispenser a propellant;

wherein the composition has at least three micelle  
20 forming compounds and the amount of the micelle forming  
compounds are each present in a concentration of from 1  
to 20 wt./wt.% of the total formulation, and the total  
concentration of alkali metal alkyl sulphate and micelle  
forming compounds is less than 50 wt./wt.% of the  
25 formulation.

16. A process according to Claim 14 wherein the alkali  
metal alkyl sulphate is sodium lauryl sulphate.

17. A process according to Claim 14 wherein the  
propellant is selected from the group consisting of  
30 tetrafluoroethane, tetrafluoropropane,  
dimethylfluoropropane, heptafluoropropane, dimethyl  
ether, n-butane and isobutane.

18. A process according to Claim 14 wherein the  
formulation comprises combinations selected from the  
35 group consisting of i) sodium lauryl sulphate,

- 37 -

polidocanol 10 lauryl ether, sodium oxo cholanyl glycine and lecithin; ii) sodium lauryl sulphate, polidocanol 10 lauryl ether, phosphatidyl choline, oleic acid; iii) sodium lauryl sulphate, polidocanol 10 lauryl ether,  
5 sodium hyaluronate and lecithin; iv) sodium lauryl sulphate, polidocanol 9 lauryl ether, triolein and polylysine; v) sodium lauryl sulphate, polyoxyethylene ether (10 lauryl), trihydroxy oxo cholanyl glycine and lecithin, and vi) sodium lauryl sulphate, polidocanol 20  
10 lauryl ether, evening of primrose oil and lecithin, and vii) sodium lauryl sulphate, trihydroxy oxo-cholanyl glycine, lecithin and chenodeoxycholate.

19. A process according to Claim 14 wherein the proteinic pharmaceutical agent is selected from the  
15 group consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, interleukins, cytokines, mono and polyclonal antibodies, immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins,  
20 insulin like growth factors (IGF), glucagon like peptides (GLP-1), large molecule antibiotics, protein based thrombolytic compounds, platelet inhibitors, DNA, RNA, gene therapeutics, antisense oligonucleotides, opiods, narcotics, hypnotics, steroids and pain  
25 killers.

20. A method for administration of a proteinic pharmaceutical agent in a buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar  
30 pharmaceutical formulation and a propellant comprising:  
i) the proteinic pharmaceutical agent in micellar form, ii) water, iii) an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 20 wt./wt.% of the total formulation, iv) at least three micelle  
35 forming compounds selected from the group consisting of

- 38 -

lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, 5 monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, 10 polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof, wherein the amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt.% of the total formulation, and the total concentration of 15 micelle forming compounds are less than 50 wt./wt.% of the formulation, v) a phenolic compound selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and vi) a propellant selected from the 20 group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.

25 21. A method according to Claim 20 wherein the pharmaceutical agent is selected from the group consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, interleukins, cytokines, mono and polyclonal antibodies, 30 immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, insulin like growth factors (IGF), glucagon like peptides (GLP-1), large molecule antibiotics, protein based thrombolytic compounds, platelet inhibitors, DNA, 35 RNA, gene therapeutics, antisense oligonucleotides,



- 39 -

opioids, narcotics, hypnotics, steroids and pain killers.

22. A method according to Claim 20 wherein the pharmaceutical agent is insulin.

5 23. A method according to Claim 21 wherein the alkali metal C8 to C22 alkyl sulphate is sodium lauryl sulphate.

24. A method according to Claim 22 wherein the alkali metal C8 to C22 alkyl sulphate is sodium lauryl  
10 sulphate.

25. A method according to Claim 20 wherein one of the micelle forming compounds is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, polidocanol alkyl  
15 ethers, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, polyoxyethylene ethers and analogues thereof, and chenodeoxycholate, the concentration such micelle forming compound being from about 1 to about 5 wt. /wt. %.

20 26. A method according to Claim 21 wherein the propellant is selected from the group consisting of tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.

25 27. A method according to Claim 22 wherein the propellant is selected from the group consisting of tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.

30 28. A method according to Claim 21 wherein the formulation comprises combinations selected from the group consisting of i) sodium lauryl sulphate, polidocanol 10 lauryl ether, sodium oxo cholanyl glycine and lecithin; ii) sodium lauryl sulphate, polidocanol 10  
35 lauryl ether, phosphatidyl choline, oleic acid; iii)

- 40 -

sodium lauryl sulphate, polidocanol 10 lauryl ether, sodium hyaluronate and lecithin; iv) sodium lauryl sulphate, polidocanol 9 lauryl ether, triolein and polylysine; v) sodium lauryl sulphate, polyoxyethylene  
5 ether (10 lauryl), trihydroxy oxo cholanyl glycine and lecithin, vi) sodium lauryl sulphate, polidocanol 20 lauryl ether, evening of primrose oil and lecithin, and vii) sodium lauryl sulphate, trihydroxy oxo-cholanyl glycine, lecithin and chenodeoxycholate.

10

## INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/CA 99/01231

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/12 A61K9/107

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 40057 A (ALLIANCE PHARMA ; TARARA THOMAS E (US); WEERS JEFFRY G (US); TREVIN) 19 December 1996 (1996-12-19) page 2, line 8 -page 2, line 12 page 2, line 19 -page 2, line 24 page 3, line 10 -page 3, line 26 page 7, line 16 -page 7, line 25	1-28
A	WO 97 42938 A (BIOZONE LAB INC) 20 November 1997 (1997-11-20) page 4, line 22 -page 5, line 2 page 5, line 15 -page 5, line 19 page 11, line 4 -page 11, line 17 -/-	1-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search

26 Apr11 2000

Date of mailing of the international search report

08. 05. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3018

Authorized officer

Borst, M

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/CA 99/01231

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 004 611 A (LEIGH STEVEN) 2 April 1991 (1991-04-02) column 2, line 49 -column 2, line 61 column 3, line 16 -column 3, line 26 column 4, line 39 -column 4, line 64	1-28
Y	WO 96 36352 A (CHANDARANA SUBASH ;MODI PANKAJ (CA)) 21 November 1996 (1996-11-21) page 3, line 2 -page 3, line 21	1-28
A	SCHREIER H ET AL: "PULMONARY DELIVERY OF LIPOSOMES" JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 24, no. 1 / 03, 1 May 1993 (1993-05-01), pages 209-223, XP000303928 ISSN: 0168-3659 page 212, right-hand column, last paragraph -page 214, right-hand column, last paragraph	1-28
P,Y	WO 99 40932 A (MODI PANKAJ) 19 August 1999 (1999-08-19) page 5, line 6 -page 5, line 26 page 7, line 14 -page 7, line 30 page 8, line 5 -page 10, line 29	1-28

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 99/01231

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 20-28 are directed to a method of treatment of the human/animal body, the search has been carried out (Rule 39.1(iv) PCT).
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/01231

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640057 A	19-12-1996	AU 704918 B	06-05-1999
		AU 6153796 A	30-12-1996
		CA 2222063 A	19-12-1996
		CN 1195981 A	14-10-1998
		EP 0833608 A	08-04-1998
		HU 9900879 A	30-08-1999
		JP 11508237 T	21-07-1999
		NO 975321 A	27-01-1998
		PL 323931 A	27-04-1998
WO 9742938 A	20-11-1997	US 5891465 A	06-04-1999
		EP 0928189 A	14-07-1999
US 5004611 A	02-04-1991	AT 75606 T	15-05-1992
		DE 3585967 A	11-06-1992
		EP 0158441 A	16-10-1985
		JP 7053661 B	07-06-1995
		JP 61044808 A	04-03-1986
		US 5053217 A	01-10-1991
		US 5141674 A	25-08-1992
WO 9636352 A	21-11-1996	US 5653987 A	05-08-1997
		AU 5642396 A	29-11-1996
		CA 2210996 A	21-11-1996
		EP 0813421 A	29-12-1997
WO 9940932 A	19-08-1999	US 6017545 A	25-01-2000
		AU 2505399 A	30-08-1999